Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $252.50 | Prev. Close $247.87 | Circuit Range N/A |
Day Range $247.00 - $256.43 | Year Range $122.80 - $256.43 | Volume 15,906 |
Average Traded $251.56 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Jan-26 | $252.50 | $247.77 | +0.00% |
06-Jan-26 | $252.50 | $247.77 | +0.49% |
02-Jan-26 | $245.06 | $246.56 | -0.32% |
31-Dec-25 | $247.81 | $247.35 | -0.17% |
30-Dec-25 | $252.50 | $247.76 | -2.17% |
29-Dec-25 | $250.78 | $253.25 | +0.40% |
26-Dec-25 | $250.24 | $252.24 | +0.60% |